Thymosin Alpha-1 vs LL-37
Thymic immunomodulatory peptide vs human cathelicidin antimicrobial peptide — adaptive vs innate immune system enhancement.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Thymosin Alpha-1 | LL-37 |
|---|---|---|
| Origin | Thymus gland (28 amino acids) | Human cathelicidin (37 amino acids) |
| Primary Mechanism | T-cell maturation, dendritic cell activation | Direct antimicrobial, innate immune activation |
| Immune Branch | Adaptive immunity (T-cells, NK cells) | Innate immunity (antimicrobial, barrier defence) |
| Approval Status | Approved in 35+ countries (Zadaxin) | Research peptide (not approved) |
| Administration | SC injection | SC injection, topical |
| Clinical Use | Hepatitis B/C, immunodeficiency, cancer adjunct | Antimicrobial research, wound healing |
| Anti-Cancer | Immunotherapy adjuvant (enhances checkpoint inhibitors) | Direct anti-tumour activity + immune modulation |
| Key Advantage | 35+ years clinical use, strong safety record | Broad-spectrum antimicrobial without resistance |
Mechanism of Action
Thymosin Alpha-1
Thymosin Alpha-1 Mechanism:
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue by Allan Goldstein in 1977. It is the primary immunoactive component of Thymosin Fraction 5.
Key actions: 1. **T-cell maturation** — Promotes differentiation of immature thymocytes into functional T-cells 2. **Dendritic cell activation** — Enhances antigen presentation and Th1 polarisation 3. **NK cell activation** — Increases natural killer cell cytotoxicity 4. **TLR signalling** — Acts through Toll-like receptors (TLR2, TLR9) as an innate-adaptive bridge 5. **Anti-inflammatory balance** — Promotes immune response without excessive inflammation
Tα1 is particularly effective in immunocompromised patients — restoring immune function without causing autoimmunity or excessive inflammation.
LL-37
LL-37 Mechanism:
LL-37 is the only human cathelicidin antimicrobial peptide — a 37-amino acid amphipathic α-helical peptide cleaved from the precursor hCAP18.
Key actions: 1. **Direct antimicrobial** — Disrupts bacterial, viral, and fungal membranes through electrostatic interaction 2. **Biofilm disruption** — Penetrates and disperses bacterial biofilms 3. **Immune cell chemotaxis** — Recruits neutrophils, monocytes, and T-cells to infection sites 4. **Wound healing** — Promotes re-epithelialisation and angiogenesis 5. **Anti-endotoxin** — Neutralises LPS, reducing sepsis-related inflammation 6. **Anti-viral** — Direct virucidal activity and enhanced interferon responses
LL-37 is a front-line innate immune effector — the body's first response to microbial invasion.
Clinical Trial Evidence
Thymosin Alpha-1 Clinical Studies
Design: Meta-analysis
Participants: 706 participants
Tα1 can regulate the balance of immune cells and alleviate immune suppression in SAP patients, including increasing CD4+ T cells and CD4+/CD8+ ratios. Tα1 may exert anti-inflammatory and extrapancreatic infection-preventive effects on SAP patients and improve their condition or prognosis. More researches are needed to validate the results.
View study — PubMed 40599771Design: Meta-analysis
Participants: 19 participants
Our study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.
View study — PubMed 37845598Design: Meta-analysis
Participants: 1,144 participants
Duration: 24 weeks
ETV plus Tα1 might lead to a higher clinical response and a lower comprehensive adverse reaction rate in HBV-related patients with cirrhosis, compared to ETV alone. However, the whole patients included in this meta-analysis were from Chinese mainland, so that more worldwide RCTs with a larger sample size are needed to verify the current findings.
View study — PubMed 33076834Design: Meta-analysis
Participants: 290 participants
We assessed the cumulative findings with trial sequential analysis to control for random errors.
View study — PubMed 23633363LL-37 Clinical Studies
Design: Systematic review
Data remain inconsistent between the studies for hBDs mainly due to heterogeneity of the results, periodontal disease diagnostic criteria and assaying technique employed. Given their role in innate immunity and their antimicrobial functions, LL-37 and α-defensins may be eligible as periodontal clinical biomarkers and could be an interesting way for therapeutic development.
View study — PubMed 31215656Design: Randomised controlled trial
Levels of four salivary antimicrobial peptides increased after exercise dependently or independently of exercise intensity and duration, whereas some salivary antimicrobial peptides did not change after exercise. These findings suggest that the secretory responses to acute exercise with different intensities and durations differ among salivary antimicrobial peptides.
View study — PubMed 39155711Design: Randomised controlled trial
Duration: 28 days
Supplementation with BB-12 is effective in managing infant colic. The effect could derive from immune and non-immune mechanisms associated with a modulation of gut microbiota structure and function.
View study — PubMed 31797399Design: Clinical trial
Strikingly, reintroduction of antimicrobial CoNS strains to human subjects with AD decreased colonization by S. aureus These findings show how commensal skin bacteria protect against pathogens and demonstrate how dysbiosis of the skin microbiome can lead to disease.
View study — PubMed 28228596Benefits Comparison
Thymosin Alpha-1 Unique Benefits
- Approved drug in 35+ countries
- Proven efficacy in hepatitis B/C
- Sepsis mortality reduction
- Cancer immunotherapy enhancement
- Decades of clinical safety data
Shared Benefits
- Immune system enhancement
- Anti-cancer potential
- Anti-inflammatory properties
- Infection response improvement
LL-37 Unique Benefits
- Broad-spectrum antimicrobial (bacteria, viruses, fungi)
- Biofilm disruption
- Low resistance development risk
- Wound healing promotion
- Endogenous molecule (vitamin D-regulated)
Research & Evidence
Thymosin Alpha-1 Research
Thymosin Alpha-1 has been studied in 100+ clinical trials with thousands of patients. Zadaxin is approved in 35+ countries for hepatitis B, and has extensive data in hepatitis C, sepsis, cancer immunotherapy, and immunodeficiency.
LL-37 Research
LL-37 research is primarily preclinical. Human data is limited to small wound healing studies and observational vitamin D-LL-37 correlation studies. No large-scale clinical trials have been completed for therapeutic LL-37 administration.
Head-to-Head Analysis
Complementary Roles:
Thymosin Alpha-1 and LL-37 operate on different branches of immunity: - Tα1: Adaptive immunity — training and activating T-cells for specific pathogen recognition - LL-37: Innate immunity — immediate, broad-spectrum antimicrobial defence
In a sequential immune response, LL-37 acts first (killing pathogens directly, recruiting immune cells), while Tα1 strengthens the adaptive response that follows (T-cell activation, immunological memory).
Evidence Quality: Tα1 has a vastly larger clinical evidence base — approved in 35+ countries with decades of use in hepatitis, cancer, and immunodeficiency. LL-37 is primarily preclinical with limited human data.
Protocol Comparison
Thymosin Alpha-1 Protocol
Thymosin Alpha-1 (Zadaxin) Clinical Protocols:
Hepatitis B: 1.6mg SC twice weekly for 6-12 months. Immunodeficiency: 1.6mg SC 2-3x weekly. Cancer Adjunct: 1.6mg SC daily during active immunotherapy. Sepsis: 1.6mg SC twice daily for 5-7 days.
Route: SC injection.
LL-37 Protocol
LL-37 Theoretical Protocols (Research-Based):
Topical (Wound Healing): 0.5-3.2 mg/ml topical gel or solution applied to wound.
Systemic (Research): SC injection doses not well-established. Limited to investigational use.
⚠️ Disclaimer: No approved therapeutic protocol exists for systemic LL-37.
Safety Profiles
Thymosin Alpha-1 Safety
Thymosin Alpha-1 Safety:
Excellent safety profile over 35+ years. Common: mild injection site reactions. No immunosuppression, no autoimmunity induction, no organ toxicity. Safe in elderly and immunocompromised patients. One of the best-tolerated immunotherapeutic agents available.
LL-37 Safety
LL-37 Safety:
Limited human safety data. Topical use well-tolerated. Systemic administration safety is largely unknown.
Theoretical concerns: At high concentrations, LL-37 can be cytotoxic to host cells (not just microbes). Pro-inflammatory at high doses. Potential to exacerbate autoimmune conditions (psoriasis involves LL-37 dysregulation).
The Verdict
Thymosin Alpha-1 is the clinically validated choice for immune enhancement — approved in 35+ countries with decades of data in hepatitis, sepsis, and cancer immunotherapy. LL-37 represents an exciting but early-stage approach to innate immunity and antimicrobial defence. They are mechanistically complementary — Tα1 for adaptive immunity, LL-37 for innate defence — and their combination has been explored in peptide stack research. For current clinical use, Tα1 is the established standard.
Frequently Asked Questions
Conclusion
Thymosin Alpha-1 and LL-37 complement each other across the adaptive-innate immune spectrum. Tα1's 35+ year clinical track record, regulatory approvals, and proven efficacy in serious infections and cancer make it the established immunotherapeutic peptide. LL-37's unique broad-spectrum antimicrobial and biofilm-disrupting properties offer a different angle on immune support that is still being translated into clinical applications. Together, they represent a comprehensive peptide approach to immune optimisation.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Thymosin Alpha-1 nor LL-37 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.